

# TABLE OF CONTENTS

## Book 3

---

Preface .....	i
Editorial Board .....	ii
Book 3 Panel .....	iii
Continuing Education and Program Evaluation Instructions .....	viii
Roles of ACCP and BPS .....	ix

## Psychiatry I

---

### MOOD DISORDERS: BIPOLAR AND MAJOR DEPRESSIVE DISORDERS

Learning Objectives .....	1
Depressive Disorder .....	1
Epidemiology .....	1
Economic Burden .....	2
Pathophysiology .....	2
Diagnostic Criteria .....	3
Major Depressive Disorder .....	3
Dysthymic Disorder .....	4
Depressive Disorder, Not Otherwise Specified .....	4
Episode or Course Specifiers .....	4
Assessment .....	5
Hamilton Rating Scale for Depression .....	6
Montgomery-Asberg Depression Rating Scale .....	6
Beck Depression Inventory .....	6
Quick Inventory of Depressive Symptoms-Self-Report .....	6
Clinical Global Impressions .....	6
Pharmacotherapy of Depression .....	6
Choosing an Antidepressant Drug .....	7
Predictors of Response .....	7
Treatment Response .....	7

Selective Serotonin Reuptake Inhibitors .....	9
Pharmacokinetics .....	10
Dosing .....	10
Drug Interactions .....	11
Adverse Effects .....	12
Venlafaxine .....	13
Pharmacokinetics .....	13
Dosing .....	13
Drug Interactions .....	14
Adverse Effects .....	14
Mirtazapine .....	14
Pharmacokinetics .....	14
Dosing .....	14
Drug Interactions .....	15
Adverse Effects .....	15
Bupropion .....	15
Pharmacokinetics .....	15
Dosing .....	15
Drug Interactions .....	15
Adverse Effects .....	15
Nefazodone .....	16
Pharmacokinetics .....	16
Dosing .....	16
Drug Interactions .....	16
Adverse Effects .....	16
Tricyclic Antidepressants .....	16
Pharmacokinetics .....	17
Dosing .....	17
Serum Concentrations .....	17
Adverse Effects .....	17
Toxicity .....	18
Monoamine Oxidase Inhibitors .....	18
Pharmacokinetics .....	18
Dosing .....	19
Drug Interactions .....	19
Adverse Effects .....	19
Over-the-counter Dietary Supplements .....	20
Augmentation Agents .....	21
Lithium .....	21

Thyroid Hormone	21
Buspirone	22
Pindolol	22
Atypical Antipsychotic Drugs	22
Psychostimulant Drugs	22
Estrogen	23
Combination Pharmacotherapy	23
Non-pharmacological Therapies	24
Electroconvulsive Therapy	24
Repetitive Transcranial Magnetic Stimulation	25
Phototherapy	25
Patient Counseling	25
Bipolar Disorder	26
Epidemiology	26
Economic Burden	26
Pathophysiology	26
Diagnostic Criteria	26
Bipolar Spectrum	26
Episode Qualifiers	27
Course of Illness	27
Assessments	27
Young Mania Rating Scale	27
Goals of Treatment	27
Pharmacotherapy	27
Treatment Response	27
Treatment of Acute Mania	28
Lithium	28
Indications	28
Lithium Pretreatment Workup	30
Pharmacokinetics/Dosing	30
Drug Interactions	30
Adverse Effects	30
Toxicity	31
Teratogenicity and Fetal Toxicity	31
Valproic Acid	31
Indication	31
Valproate Pretreatment Workup	31
Pharmacokinetics/Dosing	32
Drug Interactions	32
Adverse Effects	32
Toxicity	32
Teratogenicity	32
Carbamazepine	33
Indications	33
Carbamazepine Pretreatment Workup	33
Pharmacokinetics/Dosing	33
Drug Interactions	33
Adverse Effects	33
Toxicity	34
Teratogenicity	34
Oxcarbazepine	34
Lamotrigine	34
Pharmacokinetics/Dosing	34
Drug Interactions	35
Adverse Events	35
Other Antiepileptic Drugs	35

Atypical Antipsychotic Drugs	35
Olanzapine	35
Risperidone, Quetiapine, and Aripiprazole	36
Bipolar Depression	36
Pharmacotherapy	36
Lithium	36
Lamotrigine	36
Other Mood Stabilizer Options	36
Antidepressants	36
Mood Stabilizer Combinations	37
Difficulties in Affective Disorder Research	37
Documentation of the Pharmacotherapeutic Plan	37
Patient Counseling	37
Conclusion	38
Annotated Bibliography	39
<b>Self-Assessment Questions</b>	<b>41</b>

## SCHIZOPHRENIA AND OTHER PSYCHOSES

Learning Objectives	45
Introduction	45
Pathophysiology of Schizophrenia	45
Definition and Diagnostic Criteria	45
Positive and Negative Symptoms	46
Differential Diagnosis	46
Subtypes of Schizophrenia	47
Epidemiology	47
Proposed Etiology	47
Course of Illness	47
Consequences of Schizophrenia	48
Treatment Goals	48
Rating Scales	48
Pharmacotherapy	48
Typical Antipsychotic Drugs	48
Proposed Mechanism of Action	48
Classification/Pharmacology	48
Dosage Forms and Pharmacokinetics	49
Adverse Effects	50
Antihistaminergic Effects	50
Anticholinergic Effects	50
Cardiovascular Effects	50
Endocrinological Effects	50
Extrapyramidal Side Effects and Tardive Syndromes	50
Acute Dystonia	50
Akathisia	51
Pseudoparkinsonism	51
Tardive Dyskinesia	52
Neuroleptic Malignant Syndrome	52
Seizures	52
Atypical Antipsychotic Drugs	52
Differences from Typical Antipsychotic Drugs	52
Clozapine	53
Indications	53
Pharmacology	53
Pharmacokinetics	53
Dosing and Dosage Forms	53

Efficacy	53
Adverse Effects	53
Cautions and Contraindications	54
Drug Interactions	55
Risperidone	55
Pharmacology	55
Pharmacokinetics	55
Dosing and Dosage Forms	55
Efficacy	55
Adverse Effects	56
Extrapyramidal Side Effects of Risperidone	56
Cautions and Contraindications	56
Drug Interactions	56
Olanzapine	56
Indications	56
Pharmacology	56
Pharmacokinetics	56
Dosing and Dosage Forms	56
Efficacy	56
Adverse Effects	56
Cautions and Contraindications	56
Drug Interactions	57
Quetiapine	57
Pharmacology	57
Pharmacokinetics	57
Dosing and Dosage Forms	57
Efficacy	57
Adverse Effects	57
Cautions and Contraindications	57
Drug Interactions	57
Ziprasidone	57
Pharmacology	57
Pharmacokinetics	57
Dosing and Dosage Forms	58
Efficacy	58
Adverse Effects	58
Cautions and Contraindications	58
Drug Interactions	58
Aripiprazole	58
Pharmacology	58
Pharmacokinetics	58
Dosing and Dosage Forms	59
Efficacy	59
Adverse Effects	59
Cautions and Contraindications	59
Drug Interactions	59
Comparison of Atypical Antipsychotic Drugs	59
Efficacy	59
Adverse Effects	60
Extrapyramidal Side Effects	60
Weight Gain	60
Glucose Dysregulation	60
Elevated Triglyceride Concentrations	60
Cardiac Conduction Abnormalities	60
Treatment Considerations	61
Optimal Choice for Individual Patients	61

Algorithms and Switching Strategies	61
Polypharmacy Pros and Cons	61
Pharmacoeconomics Considerations	63
Treatment of Specific Populations or Symptom	
Domains	63
Refractory Patients	63
Pregnancy and Nursing Women	63
Comorbid Substance Abuse	63
Cognitive Symptoms	64
Patient Education	64
Conclusion	64
Annotated Bibliography	64
<b>Self-Assessment Questions</b>	<b>67</b>

## **Psychiatry II**

---

POST-TRAUMATIC STRESS DISORDER	
Learning Objectives	73
Introduction	73
Epidemiology	73
Clinical Presentation	73
Diagnosis	74
Prognosis	75
Pathophysiology	75
Assessment Measures	76
Therapeutic Approaches	76
Psychotherapeutic Treatment	76
Pharmacotherapy	77
Antidepressants	77
Monoamine Oxidase Inhibitors	77
Tricyclic Antidepressants	77
Selective Serotonin Reuptake Inhibitors	77
Acute Treatment	77
Paroxetine	78
Fluoxetine	78
Continuation Treatment	78
Relapse Prevention	78
Quality of Life	78
Other SSRIs	78
Bupropion	78
Mirtazapine	78
Venlafaxine	78
Antiadrenergic Drugs	78
Antipsychotic Drugs	79
Anxiolytics	79
Benzodiazepines	79
Buspirone	79
Cyproheptadine	79
Mood Stabilizers	80
Carbamazepine	80
Divalproex Sodium	80
Implementing a Therapeutic Plan	80
Choice of Agent	80
Time to Response	80
Expected Outcome	81

Adjunctive Therapy . . . . .	81
Pharmacoeconomic Considerations . . . . .	81
Research Needs . . . . .	83
Patient Education . . . . .	83
Annotated Bibliography . . . . .	84
<b>Self-Assessment Questions . . . . .</b>	<b>87</b>
<b>BORDERLINE PERSONALITY DISORDER</b>	
Learning Objectives . . . . .	93
Introduction . . . . .	93
Characteristics of BPD . . . . .	94
Epidemiology . . . . .	94
Symptoms . . . . .	94
Symptom Categories . . . . .	95
Assessment (Research/Clinical) . . . . .	97
Childhood Antecedents . . . . .	98
Suicide . . . . .	99
Psychobiology . . . . .	99
Amygdala: Abnormal Functioning . . . . .	100
Developmental Traumatology . . . . .	100
Low Serotonergic Neurotransmission . . . . .	100
Cerebrospinal Fluid Metabolites . . . . .	100
Hypothalamic-pituitary-adrenal Axis . . . . .	100
Dexamethasone Suppression Test . . . . .	100
Sleep Electroencephalogram . . . . .	100
Treatment Guidelines for BPD . . . . .	101
Psychotherapy . . . . .	101
Pharmacotherapy . . . . .	102
Antidepressants: Affective Dysregulation	
Symptoms . . . . .	103
Selective Serotonin Reuptake Inhibitors . . . . .	103
Tricyclic Antidepressants . . . . .	103
Monoamine Oxidase Inhibitors . . . . .	104
Dual 5-HT and Norepinephrine Reuptake	
Inhibitors . . . . .	105
Mood Stabilizers: Affective Dysregulation	
Symptoms . . . . .	105
Neuroleptics . . . . .	112
Anxiolytics . . . . .	113
Therapeutic Alternatives . . . . .	113
Omega-3 Fatty Acid . . . . .	113
Naltrexone . . . . .	114
Patient Education . . . . .	114
Socioeconomic Considerations . . . . .	114
Psychosocial Aspects . . . . .	114
Economic Considerations . . . . .	115
Conclusion . . . . .	115
Annotated Bibliography . . . . .	116
<b>Self-Assessment Questions . . . . .</b>	<b>119</b>

### Psychiatry III

#### GERIATRIC PSYCHIATRY

Learning Objectives . . . . .	127
Introduction . . . . .	127

Importance of Geriatric Psychiatry . . . . .	127
Definitions . . . . .	128
Chronic Illnesses and Comorbidities . . . . .	128
Age-related Changes . . . . .	129
Geriatric Brain Function . . . . .	129
Drug Handling: Pharmacokinetics . . . . .	129
Absorption . . . . .	129
Distribution . . . . .	129
Renal Clearance . . . . .	129
Hepatic Clearance . . . . .	130
Drug Responsiveness: Pharmacodynamics . . . . .	130
Receptor Influence . . . . .	130
Homeostatic Mechanisms . . . . .	130
Adherence Issues . . . . .	131
Disordered Behaviors . . . . .	131
Delirium . . . . .	131
Dementia . . . . .	133
Diagnosis . . . . .	133
Screening Tools . . . . .	134
Treatment . . . . .	134
Non-pharmacological Intervention Strategies . . . . .	134
Pharmacological Treatment Strategies . . . . .	135
Antipsychotic Drugs . . . . .	135
Clozapine . . . . .	135
Risperidone . . . . .	136
Olanzapine . . . . .	136
Quetiapine . . . . .	136
Ziprasidone . . . . .	137
Aripiprazole . . . . .	137
Adverse Effects and Concerns with	
Antipsychotic Drugs . . . . .	137
Movement Disorders . . . . .	137
Dystonia . . . . .	138
Akathisia . . . . .	138
Parkinsonism . . . . .	138
Tardive Dyskinesia . . . . .	138
Orthostasis and Falls . . . . .	139
Anticholinergic and Antihistaminic Effects . . . . .	139
Weight Gain . . . . .	139
Type 2 Diabetes Mellitus . . . . .	140
Cerebrovascular Events . . . . .	140
Ongoing BPSD Clinical Trials with	
Antipsychotic Drugs . . . . .	140
Antipsychotic Drug Discontinuation . . . . .	141
Alternatives to Antipsychotic Drugs . . . . .	141
Benzodiazepines . . . . .	141
Buspirone . . . . .	141
Mood Stabilizers . . . . .	141
Carbamazepine . . . . .	141
Divalproex Sodium . . . . .	141
Gabapentin . . . . .	142
Cholinesterase Inhibitors . . . . .	142
Antidepressants . . . . .	142
Schizophrenia . . . . .	143
Early-onset versus Late-onset Disease . . . . .	143
Behavioral and Psychological Symptoms of	

Dementia Versus Schizophrenia Symptoms	143
Treatment Issues	143
Bipolar Disorder	144
Treatment	144
Lithium	145
Anticonvulsants	145
Antipsychotic Drugs	145
Antidepressants	145
Combination Therapy	145
Other	145
Psychosocial Therapy	145
Alcohol Abuse	146
Attention-deficit Hyperactivity Disorder	146
Depression	146
Epidemiology	146
Depression and Outcomes	147
Diagnosis	147
General Issues and Symptomatology	147
Screening and Diagnostic Tools	147
Diagnostic Issues: Life Events and Underdiagnosis	147
Depression and Dementia	148
Diagnostic Issues	148
Pseudodementia	148
Depression in Established Dementia	148
Drug-induced Depression	148
Depression and Functioning	148
Depression and Medical Illness	148
Treatment of Geriatric Depression	149
General Points	149
Heterocyclic Antidepressants	149
Tricyclic Antidepressants	149
Venlafaxine	149
Monoamine Oxidase Inhibitors	150
Selective Serotonin Reuptake Inhibitors	150
General Points	150
Citalopram and Escitalopram	150
Fluoxetine	150
Paroxetine	151
Sertraline	151
Other Atypical Antidepressants	151
Bupropion	151
Mirtazapine	151
Nefazodone	151
Psychomotor Stimulants	151
Treatment Duration	152
Treatment of Dysthymia or Minor Depression	152
Psychotic Depression	152
Augmentation Strategies	152
Substitution	152
Patient Education	153
Anxiety	153
Prevalence	153
Differential Diagnosis	153
Treatment of Anxiety States	153
General Points	153

Benzodiazepines	153
Central Nervous System Depressants	154
Buspirone	154
$\beta$ -Adrenergic Antagonists	154
Antidepressants	154
Sedating Antihistamines	154
Antipsychotic Drugs	154
Non-pharmacological Therapies	155
Patient Follow-up	155
Sleep Disorders	155
Characteristics, Epidemiology, and Effect on Outcomes	155
Non-pharmacological Therapy	155
Pharmacotherapy	156
Antihistamines	156
Barbiturates and Chloral Hydrate	156
Benzodiazepines	156
Nonbenzodiazepine Hypnotics	157
Antidepressants	157
Melatonin	157
Antipsychotic Drugs	157
Summary: Role of the Pharmacist	157
Annotated Bibliography	157
<b>Self-Assessment Questions</b>	<b>159</b>

#### METABOLIC, ENDOCRINOLOGIC, AND CARDIOVASCULAR ADVERSE EFFECTS OF PSYCHOTROPIC DRUGS

Learning Objectives	163
Introduction	163
Metabolic Disturbances	163
Epidemiology	163
Weight Gain	163
Lipid Abnormalities	164
Diabetes Mellitus	164
Pathophysiology and Etiology	165
Weight Gain	165
Lipid Abnormalities	165
Diabetes Mellitus	165
Clinical Evidence	166
Weight Gain	166
Antipsychotic-associated Weight Gain	166
Antidepressant-associated Weight Gain	166
Lipid Abnormalities	166
Diabetes Mellitus	167
Monitoring and Therapeutic Considerations	168
Sexual Dysfunction	169
Epidemiology	169
Pathophysiology and Etiology	170
Clinical Evidence	171
Monitoring	171
Therapeutic Considerations	171
Hyperprolactinemia	173
Epidemiology	173
Pathophysiology and Etiology	174
Clinical Evidence	174

Monitoring .....	175
Therapeutic Considerations .....	175
Cardiovascular Disturbances .....	175
Epidemiology .....	175
Clinical Evidence .....	176
Blood Pressure .....	176
Congestive Heart Failure and Myocarditis .....	176
QTc Interval Prolongation .....	176
Cerebrovascular Events .....	177
Conclusion .....	177
Annotated Bibliography .....	178
<b>Self-Assessment Questions .....</b>	<b>179</b>